drugset / Trial / NCT01301027
Effect of Adipokines in Hemodialysis Patients
Completed
95 enrolled
University of Utah
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabUniversity of Colorado, Denver · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a double blinded randomized clinical trial of pioglitazone vs. placebo in overweight or obese, diabetic and non-diabetic hemodialysis patients. This study will examine whether pioglitazone modulates adipokine production by adipose tissue in hemodialysis patients and whether these changes result in reduction of inflammation, insulin resistance and oxidative stress and increase in muscle mass. In addition, this study will also examine the associations of adiposity with adipokines and the metabolic milieu in hemodialysis patients to better understand the biology of adipocytes in uremic milieu.
Timeline
- Start
- 2008-05
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pioglitazone | Small molecule | 30 mg | Oral |